General Information of This Antibody
Antibody ID
ANI0THIPX
Antibody Name
SHR-A1403 mAb
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG2-kappa
Antigen Name
Hepatocyte growth factor receptor (MET)
 Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
QVQLVESGGGVVQPGRSLRLSCAASGFSLSNYGVHWVRQAPGKGLEWLAVIWSGGSTNYA
AAFVSRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSS
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFR
VVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Light Chain Sequence
DIVLTQSPDSLAVSLGERATINCRADKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLAS
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRDLPPTFGQGTKLEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
The Activity Data of This Antibody
Antibody Activity Information 1 [1]
Dissociation Constant (Kd)
15.8
nM
Antibody Function Confirm the effect of the drug conjugation with the anti c-Met mAb and ADC on binding activity to target.
Antibody Antigen Binding Assay The binding affinity of SHR-A1403 to c-Met protein derived from human, cynomolgus monkey, and mouse was evaluated by the KD determined using Biacore assays and compared to that of naked SHR-A1403 mAb.
Antibody Activity Information 2 [1]
Dissociation Constant (Kd)
28.4
nM
Antibody Function Confirm the effect of the drug conjugation with the anti c-Met mAb and ADC on binding activity to target.
Antibody Antigen Binding Assay The binding affinity of SHR-A1403 to c-Met protein derived from human, cynomolgus monkey, and mouse was evaluated by the KD determined using Biacore assays and compared to that of naked SHR-A1403 mAb.
Each Antibody-drug Conjugate Related to This Antibody
References
Ref 1 A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Front Oncol. 2021 Mar 17;11:634881. doi: 10.3389/fonc.2021.634881. eCollection 2021.